Pick 2–10 funds, stocks or ETFs to see their returns, risk, costs and highlights on one page
* Fewer than 12 months: the year the fund started reporting NAV, or the current year
Counts only the top holdings with available data, not the whole portfolio · Pick a pair below for details
| DAOL-CHINABIO | BCARE | |
|---|---|---|
| Only in DAOL-CHINABIO | ||
| WuXi Biologics | 9.80% | N/A |
| CSPC Pharmaceutical Group | 6.71% | N/A |
| JD Health International | 6.39% | N/A |
| Innovent | 4.88% | N/A |
| Only in BCARE | ||
 Eli Lilly and Co | N/A | 8.44% |
 Merck & | N/A | 5.46% |
 Johnson & Johnson | N/A | 4.76% |
 AstraZeneca | N/A | 3.87% |
29 Jan 2026 → 2 Nov 2026
| Fund | Return per year | Volatility per year | Sharpe |
|---|---|---|---|
| BCARE | +15.27% | 16.19% | 0.94 |
| DAOL-CHINABIO | −14.77% | 35.69% | −0.41 |
Sharpe here = annual return ÷ annual volatility, without deducting the risk-free rate, calculated from NAV over the selected period · Periods shorter than 1 year use the cumulative return instead of the annual return
| Drag a column header to reorder | DAOL-CHINABIO | BCARE |
|---|---|---|
Fund details | ||
| Fund size | 73.32 million | 4,712 million |
| Inception date | 29 Jan 2026 | 29 Aug 2007 |
| Master fund | Hang Seng Biotech Index ETF | Wellington Global Health Care Equity Fund |
| Dividend policy | Does not pay | Does not pay |
Risk and currency hedging | ||
| Risk level | 7 | 7 |
| Hedging policy | Hedged at the manager's discretion | Hedged at the manager's discretion |
| Share hedged | 73.46% | 47.41% |
Minimum purchase and redemption | ||
| First purchase | 1 THB | 500 THB |
| Subsequent purchase | 1 THB | 500 THB |
| Redemption (amount) | No minimum | No minimum |
| Redemption (units) | No minimum | No minimum |
| Balance (amount) | No minimum | No minimum |
| Balance (units) | 100 units | No minimum |
Order cut-off and redemption payment | ||
| Buy before | 13:30 | 15:30 |
| Redeem before | 13:30 | 15:30 |
| Redemption paid | T+3 | T+4 |
